Cambridge Investment Research Advisors Inc. reduced its position in Masimo Co. (NASDAQ:MASI – Get Rating) by 8.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,209 shares of the medical equipment provider’s stock after selling 303 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Masimo were worth $475,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the company. IFP Advisors Inc boosted its position in Masimo by 123.6% during the 3rd quarter. IFP Advisors Inc now owns 161 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 89 shares during the period. GHP Investment Advisors Inc. acquired a new stake in Masimo during the 3rd quarter worth approximately $53,000. Lazard Asset Management LLC lifted its position in shares of Masimo by 20.0% in the 1st quarter. Lazard Asset Management LLC now owns 485 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 81 shares during the period. Archer Investment Corp lifted its position in shares of Masimo by 40.7% in the 4th quarter. Archer Investment Corp now owns 550 shares of the medical equipment provider’s stock worth $81,000 after purchasing an additional 159 shares during the period. Finally, VitalStone Financial LLC acquired a new position in shares of Masimo during the 4th quarter valued at $88,000. 87.67% of the stock is owned by institutional investors.
Masimo Stock Down 0.3 %
Shares of NASDAQ MASI opened at $157.97 on Friday. The company has a quick ratio of 1.30, a current ratio of 2.16 and a debt-to-equity ratio of 0.67. Masimo Co. has a 52 week low of $108.89 and a 52 week high of $198.00. The firm’s fifty day moving average is $180.91 and its 200 day moving average is $164.03. The company has a market cap of $8.34 billion, a price-to-earnings ratio of 72.47 and a beta of 0.87.
Analyst Ratings Changes
A number of analysts have commented on the stock. BTIG Research boosted their price target on shares of Masimo from $195.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, April 17th. Stifel Nicolaus raised their price objective on shares of Masimo from $200.00 to $205.00 in a report on Wednesday, May 10th. Needham & Company LLC increased their target price on shares of Masimo from $192.00 to $207.00 in a research report on Wednesday, May 10th. Raymond James increased their target price on shares of Masimo from $187.00 to $198.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 1st. Finally, Piper Sandler raised their price objective on shares of Masimo from $135.00 to $150.00 and gave the company a “neutral” rating in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Masimo has a consensus rating of “Moderate Buy” and an average price target of $188.88.
Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge.
- Get a free copy of the StockNews.com research report on Masimo (MASI)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.